PatientsVille.com Logo

HAEMATOMA and Tikosyn

PatientsVille

HAEMATOMA Symptoms and Causes

Bleeding is the loss of blood. It can happen outside or inside the body. You may bleed when you get a cut or other wound. Bleeding can also be due to an injury to internal organs.

Sometimes bleeding can cause other problems. A bruise is bleeding under the skin. Some strokes are caused by bleeding in the brain. Other bleeding, such as gastrointestinal bleeding, coughing up blood, or vaginal bleeding, can be a symptom of a disease.

Normally, when you bleed, your blood forms clots to stop the bleeding. Severe bleeding may require first aid or a trip to the emergency room. If you have a bleeding disorder, your blood does not form clots normally.

Check out the latest treatments for HAEMATOMA

HAEMATOMA treatment research studies

Tikosyn clinical trials, surveys and public health registries


Find Drug Side Effect reports



Tikosyn Side Effects

Atrial Fibrillation (267)
Dizziness (156)
Fatigue (116)
Dyspnoea (110)
Headache (94)
Electrocardiogram Qt Prolonged (86)
Heart Rate Increased (83)
Condition Aggravated (79)
Arrhythmia (74)
Asthenia (68)
Nausea (62)
Chest Pain (61)
Diarrhoea (52)
Palpitations (48)
Feeling Abnormal (48)
Torsade De Pointes (45)
Urinary Tract Infection (40)
Blood Pressure Increased (39)
Cardiac Disorder (35)
Insomnia (34)
Heart Rate Irregular (32)
Pneumonia (31)
Hypertension (31)
Death (30)
Blood Potassium Decreased (30)
Malaise (30)
Ventricular Tachycardia (30)
Pain In Extremity (28)
Weight Decreased (27)
Vision Blurred (26)
Arthralgia (25)
Heart Rate Decreased (25)
Cough (25)
Weight Increased (24)
Anxiety (23)
Nasopharyngitis (22)
Tremor (21)
Hyperhidrosis (21)
Blood Creatinine Increased (20)
Chest Discomfort (20)
Renal Impairment (20)
Fall (20)
Muscle Spasms (19)
Vomiting (19)
Infection (19)
Blood Pressure Decreased (19)
Bronchitis (18)
Cardiac Failure Congestive (18)
Depression (18)
Dysphagia (18)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

HAEMATOMA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting The Effect of Subdural Drain Placement After Burr Hole Evacuation of Chronic Subdural Haematomas on Recurrence: a Prospective Randomised-controlled Multi-centre Study
Conditions: Chronic Subdural Hematoma;   Subdural Drain
Intervention: Device: Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma
Outcome Measures: Significant recurrent chronic subdural hematoma i.e. requiring repeat operative drainage at six months after the primary operation;   1. Functional performance in terms of the Extended Glasgow Outcome Scale;   Added neurological deficit;   Surgery-related complications;   Death;   Modified Rankin Score
2 Recruiting To Scan or Not to Scan: The Role of Follow-up CT Scanning for Management of Chronic Subdural Hematoma After Neurosurgical Evacuation
Condition: Chronic Subdural Hematoma
Intervention: Other: cranial CT scan
Outcome Measures: modified Rankin Scale;   Rate of reoperation;   Mini Mental Status;   NIHSS;   QLQ-C30;   Total length of hospitalisation;   Influence of the size and radiological features of the hematoma on rate of recurrence
3 Not yet recruiting Effect and Safety Study of Atorvastatin to Treat Chronic Subdural Hematoma
Condition: Chronic Subdural Hematoma
Interventions: Drug: Atorvastatin;   Drug: placebo
Outcome Measures: Hematoma Reduced Amount.;   The consciousness score (MGS-GCS) and outcome score (GOS, ADL-BI Scale) in subjects;   Changes of neurological symptoms and signs;   Changes of routine blood test and coagulation results
4 Recruiting Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma
Condition: Chronic Subdural Hematoma
Interventions: Drug: Dexamethasone;   Procedure: Burr Hole Craniostomy
Outcome Measures: modified Rankin Score of 0, 1 or 2;   Rate of treatment failure;   modified Rankin Score;   Glasgow Coma Score;   Markwalder Grading Score
5 Not yet recruiting Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma?
Conditions: Head Trauma;   Traumatic Brain Injury;   Chronic Subdural Hematoma
Interventions: Drug: discontinuation of aspirin therapy;   Drug: continuation of aspirin therapy
Outcome Measures: Occurrence of CSDH;   Intervention for surgical evacuation of CSDH;   Occurrence of other clinically significant intracranial hemorrhage;   Intervention for surgical evacuation of other intracranial hemorrhage;   Occurrence of clinically significant cerebrovascular, cardiovascular, thrombolic, or embolic event;   Intervention for treatment of cerebrovascular, cardiovascular, thrombolic, or embolic event
6 Recruiting A Prospective Randomized Study Evaluating the Recurrence Rate of Chronic Subdural Hematoma After Placing a Subperiosteal Drainage Compared to a Subdural Drainage
Condition: Chronic Subdural Hematoma
Interventions: Procedure: Subdural Drainage;   Procedure: Subperiosteal Drainage
Outcome Measures: Recurrence Rate;   Complication rate (Morbidity);   Mortality;   Outcome: Markwalder Score;   Outcome: modified Ranking Score;   Outcome: Glasgow Outcome Score
7 Recruiting Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas
Condition: r-Hirudin (Thrombexx) Efficacy in Treatment of Haematomas
Interventions: Drug: active product ( Thrombexx) assigned to arm 1;   Other: Placebo assigned to arm 2
Outcome Measures: Size of Haematoma;   Size of oedema;   Severity of Pain;   Change in Colour
8 Recruiting To Study the Effect of Early Cooling in Acute Subdural Hematoma Patients
Condition: Subdural Hematoma, Traumatic
Intervention: Other: Hypothermia
Outcome Measure: Extended Outcome Glasgow Scale
9 Not yet recruiting Interest of Oral Corticosteroids in the Treatment of Chronic Subdural Hematomas. Prospective Randomized Multicenter Trial
Condition: Chronic Intracranial Subdural Hematoma
Interventions: Drug: prednisone;   Drug: placebo
Outcome Measures: the evaluation of efficacy of postoperative corticosteroid treatment in patients group compared with placebo;   Evaluation of mortality rate at one year;   Evaluation of quality of life at one year;   evaluation of tolerance at one year
10 Recruiting Strategy of Continued Versus Interrupted Dabigatran at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
Condition: Hematoma
Intervention: Drug: Dabigatran
Outcome Measures: Clinically significant hematoma;   Composite of major peri-operative bleeding events and thrombo-embolic events
11 Recruiting Irrigation of Chronic Subdural Hematomas - is More Better?
Condition: Hematoma, Subdural, Chronic
Intervention: Procedure: Burr hole surgery with various drainage techniques
Outcome Measures: reoperations;   continuous irrigation versus other drainage;   perioperative death;   survival;   surgical complications
12 Not yet recruiting Hematoma Block for Reduction of Distal Radius Fractures
Condition: Fractures of the Distal Radius
Interventions: Drug: Lidocaine HCl 2% .;   Drug: Lidocaine HCl 1%
Outcome Measures: This study will be measured effective in terms of pain relieving with Visual Analog Scale.;   This study will be measured safe in terms of complications to injection.
13 Not yet recruiting Decompressive Craniectomy After Removing Hematoma to Treat Intracerebral Hemorrhage
Condition: Intracranial Hemorrhages
Interventions: Procedure: Decompressive Craniectomy;   Procedure: non-Decompressive Craniectomy
Outcome Measures: Mortality and disability;   Occurrence of second Surgery
14 Unknown  The 2-stage Approach for Reducing Posterior Wall Puncture During the Internal Jugular Vein Catheterization
Condition: Hematoma
Intervention: Procedure: Central venous catheterization
Outcome Measure: hematoma formation
15 Unknown  Timing of Postoperative Drain Removal Following Parotidectomy - a Prospective Randomized Controlled Study
Condition: Parotidectomy
Interventions: Other: Early Drain Removal;   Other: Late Drain Removal
Outcome Measures: Rate of hematoma formation;   Rate of infection
16 Recruiting Platelet Transfusion in Acute Intracerebral Hemorrhage
Condition: Intracerebral Hemorrhage
Intervention: Biological: platelets
Outcome Measures: Hematoma growth within 24 h measured as increase in hematoma volume observed by head CT;   Glasgow Outcome Score;   Cardiovascular death occurring within the treatment period;   Death due to any cause occurring within the treatment period;   Acute myocardial infarction;   Venous thromboembolism
17 Unknown  The Spot Sign for Predicting and Treating ICH Growth Study
Condition: Intracerebral Hemorrhage
Interventions: Drug: recombinant activated factor VII;   Drug: placebo
Outcome Measures: Life-threatening thromboembolic complications defined as development of (1) acute myocardial ischemia; (2) acute cerebral ischemia; and (3) acute pulmonary embolism;   The rate of hematoma growth among spot sign positive subjects at 24 hours, comparing subjects treated with rFVIIa to those treated with placebo. Hematoma growth will be defined as a > 33% or > 6 cc increase in volume.;   The sensitivity and specificity of the spot sign for predicting hematoma growth;   Incidence of other potentially study drug related thromboembolic complications such as deep venous thrombosis and elevations in troponin not associated with ECG changes;   Ninety-day outcomes among spot positive subjects, dichotomized as modified Rankin Scale score of 0-4 verses 5-6, comparing subjects treated with rFVIIa to those treated with placebo;   The positive and negative predictive values of the spot sign and the accuracy of the site investigators for correct identification of the spot sign as compared to a blinded study neuroradiologist.;   Rate of total hemorrhage volume growth (hematoma + IVH) among spot-positive subjects.
18 Recruiting Clinical Re-evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy
Condition: Intracerebral Hemorrhage
Interventions: Drug: ICH-1(herbal medicine with Hirudo, Tabanus);   Drug: placebo;   Drug: ICH-2(herbal medicine without Hirudo, Tabanus)
Outcome Measures: Hematoma enlargement;   fatality rate;   modified rankin scale;   National Institute of Health of stroke scale
19 Recruiting Evaluation of the LMWH Thromboprophylaxis in Pregnancy
Condition: Pregnancy
Intervention:
Outcome Measures: Effect of standard prophylactic dose of LMWH on coagulation in pregnant women;   Evaluation of the possible influence of LMWH on the potential risk of spinal hematoma development during neuraxial blockade in pregnancy.
20 Recruiting Immediate Mobilization After Cardiac Catheterisation
Conditions: Vascular Access Complication;   Comfort
Interventions: Other: Immediate mobilization;   Other: Two hours bedrest
Outcome Measures: Hematoma> 5 cm;   The presence of hematoma> 10 cm in diameter;   The presence of hematoma 2-5 cm in diameter;   Oozing or bleeding from the puncture site;   Comfort rating (NRS scale)